港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

2,217.549

-44.854-1.98%

漲家數：- -

跌家數：8

平家數：- -

市盈率：- -

高：2,276.820

開：2,262.471

低：2,193.695

收：2,262.402

資料載入中...

康龍化成取得高效液相色譜柱清洗裝置專利，改善清洗液利用效率較低的問題

CRO指數盤中漲幅擴大至3%，美迪西漲停，昭衍新藥、畢得醫藥、陽光諾和、益諾思跟漲。

泰格醫藥盤中異動急速拉昇5.03%

昭衍新藥盤中異動早盤大幅上漲5.05%報20.400港元

敬告客戶-以下稿子現予以撤銷-美國議員再次關注 GenScript 與中國的關係

藥明生物(02269.HK)7月8日耗資3億港元回購1168萬股

【藥明生物(02269.HK)7月8日斥資2.99億港元回購1168萬股】智通財經APP訊，藥明生物(02269.HK)

生物科技復興有望？藥明康德CRDMO模式加速歐洲創新進程

港交所文件顯示，貝萊德H股持倉比例從7月2日的5.49%降至4.98%

上海萊士：SR604注射液進入Ⅱb期臨牀試驗研究

上海萊士(002252.SZ)：SR604注射液進入Ⅱb期臨牀試驗研究

聯環藥業(600513.SH)：LH-1801項目從臨牀試驗成功到最終上市銷售並實現盈利面臨多重關鍵環節的重大不確定性

【恆瑞醫藥(01276.HK)：SHR-2173注射液獲藥物臨牀實驗批准】智通財經APP訊，恆瑞醫藥(01276.HK)

【恆瑞醫藥(01276.HK)附屬獲得國家藥監局核准簽發關於HRS-9821吸入粉霧劑的《藥物臨牀試驗批准通知書》】智通

【博瑞醫藥：噻託溴銨吸入粉霧劑獲藥物臨牀試驗批准】博瑞醫藥公告，控股子公司艾特美（蘇州）醫藥科技有限公司近日收到國家藥監局簽發的《藥物臨牀試驗批准通知書》，同意艾特美噻託溴銨吸入粉霧劑開展用於慢性阻塞性肺疾病（COPD）的臨牀試驗。噻託溴銨吸入粉霧劑2022年至2024年國內銷售額分別為5.55億元、5.22億元、4.93億元。藥品在獲得批准後尚需開展臨牀試驗並經批准後方可生產上市，短期內對公司經營業務不會產生較大影響。

藥明康德(02359)7月8日斥資2000.76萬元回購28.5萬股A股

恆瑞醫藥(600276.SH)：HRS-9821吸入粉霧劑獲得藥物臨牀試驗批准

金斯瑞生物科技07月08日獲主力加倉1288.5萬元

康龍化成07月08日主力淨流入2024.8萬元散户資金拋售

維亞生物07月08日獲主力加倉98.1萬元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=12"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":2217.5486,"timestamp":1753085317147,"preClose":2262.4023,"halted":0,"volume":92790953,"delay":0,"changeRate":-0.019826,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-44.85376,"latestTime":"07-21 16:00:00","open":2262.471,"high":2276.8196,"low":2193.695,"amount":2444384021,"amplitude":0.036742,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1753147800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1753061400000,1753070400000],[1753074000000,1753084800000]],"pbRate":2.678209,"peRate":12.781827,"turnoverRate":0.008008,"increases":0,"decrements":8,"flats":0,"marketCap":508098054144,"floatMarketCap":204119770880},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":2276.8196,"amplitude":0.036742,"preClose":2262.4023,"low":2193.695,"pbRate":"2.678209","latestPrice":2217.5486,"volume":92790953,"delay":0,"open":2262.471,"prevYearClose":1395.7731,"prevWeekClose":2262.402,"prevMonthClose":1988.255,"prevQuarterClose":1988.255,"fiveDayClose":2114.666,"twentyDayClose":1883.162,"sixtyDayClose":1645.051,"secType":"PLATE","market":"HK","turnoverRate":0.008008,"peRate":12.781827,"marketCap":508098054144,"floatMarketCap":204119770880,"timestamp":1753085317147,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":0,"down":8,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:12,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550020502","title":"康龍化成取得高效液相色譜柱清洗裝置專利，改善清洗液利用效率較低的問題","url":"https://stock-news.laohu8.com/highlight/detail?id=2550020502","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550020502?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 12:52","pubTimestamp":1752036752,"startTime":"0","endTime":"0","summary":"金融界2025年7月9日消息，国家知识产权局信息显示，康龙化成 药物开发有限公司取得一项名为“一种高效液相色谱柱清洗装置”的专利，授权公告号CN223070086U，申请日期为2024年08月。天眼查资料显示，康龙化成（宁波）药物开发有限公司，成立于2018年，位于宁波市，是一家以从事研究和试验发展为主的企业。通过天眼查大数据分析，康龙化成（宁波）药物开发有限公司参与招投标项目9次，专利信息8条，此外企业还拥有行政许可20个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709130420953bb816&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709130420953bb816&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","03759","BK1141"],"gpt_icon":0},{"id":"2550506101","title":"CRO指數盤中漲幅擴大至3%，美迪西漲停，昭衍新藥、畢得醫藥、陽光諾和、益諾思跟漲。","url":"https://stock-news.laohu8.com/highlight/detail?id=2550506101","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550506101?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 11:05","pubTimestamp":1752030351,"startTime":"0","endTime":"0","summary":"CRO指数盘中涨幅扩大至3%，美迪西涨停，昭衍新药、毕得医药、阳光诺和、益诺思跟涨。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/09110551578183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK1576","BK0216","688073","06127","603127","688710","688202","688621"],"gpt_icon":0},{"id":"2550505560","title":"泰格醫藥盤中異動 急速拉昇5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550505560","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550505560?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 10:30","pubTimestamp":1752028256,"startTime":"0","endTime":"0","summary":"2025年07月09日早盘10时30分，泰格医药股票出现异动，股价大幅拉升5.03%。截至发稿，该股报45.900港元/股，成交量412.67万股，换手率3.35%，振幅6.64%。机构评级方面，在所有13家参与评级的机构中，62%的券商给予买入建议，23%的券商给予持有建议，15%的券商给予卖出建议。泰格医药股票所在的生物技术行业中，整体涨幅为0.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709103056a43f3312&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709103056a43f3312&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1576","BK1141","BK1583"],"gpt_icon":0},{"id":"2550055995","title":"昭衍新藥盤中異動 早盤大幅上漲5.05%報20.400港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550055995","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550055995?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 10:26","pubTimestamp":1752027998,"startTime":"0","endTime":"0","summary":"2025年07月09日早盘10时26分，昭衍新药股票出现异动，股价大幅拉升5.05%。截至发稿，该股报20.400港元/股，成交量334.957万股，换手率2.81%，振幅8.08%。资金方面，该股资金流入2886.75万港元，流出2312.79万港元。最近的财报数据显示，该股实现营业收入3.11亿港元，净利润4,455.80万港元，每股收益0.0542港元，毛利8,907.85万港元，市盈率191.14倍。昭衍新药股票所在的生物技术行业中，整体涨幅为1.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102638a43f30a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102638a43f30a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","06127"],"gpt_icon":0},{"id":"2550575453","title":"敬告客戶-以下稿子現予以撤銷-美國議員再次關注 GenScript 與中國的關係","url":"https://stock-news.laohu8.com/highlight/detail?id=2550575453","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550575453?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 05:30","pubTimestamp":1752010205,"startTime":"0","endTime":"0","summary":"敬告客户-以下稿子现予以撤销-美国议员再次关注 GenScript 与中国的关系STORY_NUMBER: L4T3T51DESTORY_DATE: 08/07/2025STORY_TIME: 2130 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nL4T3T51DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","BK4588","BK4585","HK0000320264.USD","BK1583","BK4139","BK4505","HK0000306685.HKD","BK1576","01548","BK1141","HK0000320223.HKD","LEGN"],"gpt_icon":0},{"id":"2549531540","title":"藥明生物(02269.HK)7月8日耗資3億港元回購1168萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2549531540","media":"格隆汇","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549531540?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 21:08","pubTimestamp":1751980085,"startTime":"0","endTime":"0","summary":"格隆汇7月8日丨药明生物(02269.HK)公告，7月8日耗资3亿港元回购1168万股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/08210851569366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2039709279.SGD","LU0348735423.USD","LU0051755006.USD","LU0326950275.SGD","SG9999002562.SGD","LU0823426308.USD","LU0456827905.SGD","LU1242518857.USD","LU0516422952.EUR","LU0572944931.SGD","LU0140636845.USD","LU0516423091.SGD","LU0307460666.USD","LU0456846285.SGD","LU0516422366.SGD","LU1880383366.USD","LU0823426480.USD","BK1576","LU1794554557.SGD","02269","BK1521","LU1242518931.SGD","LU0359202008.SGD","LU0588546209.SGD","LU0359201612.USD","BK1610","IE00B0JY6N72.USD","LU0043850808.USD","LU0039217434.USD","LU1720050803.USD","SG9999002463.SGD","LU1688375341.USD","LU0348825331.USD","LU0417516738.SGD","LU0516423174.USD","LU0708995583.HKD","LU0052750758.USD","LU0979878070.USD","BK1589","BK1141","LU0320764599.SGD","LU0856984785.SGD","LU0516422440.USD","LU0417516902.SGD","LU0181495838.USD","LU0327786744.USD","LU0819121731.USD"],"gpt_icon":0},{"id":"2549540892","title":"【藥明生物(02269.HK)7月8日斥資2.99億港元回購1168萬股】智通財經APP訊，藥明生物(02269.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2549540892","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549540892?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 21:05","pubTimestamp":1751979904,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1576","LU0516423174.USD","LU0359202008.SGD","LU0588546209.SGD","BK1521","LU0979878070.USD","BK1141","LU1242518931.SGD","BK1589","02269","LU0043850808.USD","LU0516422952.EUR","LU0456827905.SGD","LU0348825331.USD","LU0516422366.SGD","LU1880383366.USD","LU0572944931.SGD","LU0051755006.USD","SG9999002463.SGD","LU0819121731.USD","LU0320764599.SGD","IE00B0JY6N72.USD","LU0359201612.USD","LU0039217434.USD","LU1242518857.USD","LU0181495838.USD","LU0348735423.USD","LU0326950275.SGD","LU0052750758.USD","LU0516423091.SGD","LU1688375341.USD","LU0856984785.SGD","SG9999002562.SGD","LU0823426480.USD","LU0417516902.SGD","LU0417516738.SGD","LU0516422440.USD","LU0823426308.USD","LU1720050803.USD","LU2039709279.SGD","LU0307460666.USD","BK1610","LU0708995583.HKD","LU0327786744.USD","LU0140636845.USD","LU1794554557.SGD","LU0456846285.SGD"],"gpt_icon":0},{"id":"2549154145","title":"生物科技復興有望？藥明康德CRDMO模式加速歐洲創新進程","url":"https://stock-news.laohu8.com/highlight/detail?id=2549154145","media":"同壁财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549154145?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 19:13","pubTimestamp":1751973228,"startTime":"0","endTime":"0","summary":"药明康德“一站式、端到端”的CRDMO模式能够提供覆盖药物开发完整价值链的能力、技术和规模设施，显著降低了Biotech在工艺开发、监管合规和产能供应等方面的风险。通过与药明康德合作，这家公司不仅能获得高效的执行落地能力，还能吸收关键的产业化经验，从而加速新药研发进程。2025年第一季度，药明康德的小分子D&M管线新增了203个分子，其中R到D转化的分子有75个，充分体现了CRDMO平台在分子转化上的优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708192508a69d17a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708192508a69d17a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0052750758.USD","LU2242644610.SGD","LU2125910500.SGD","BK1576","LU2045819591.USD","LU0708995583.HKD","BK1583","603259","LU0320764599.SGD","02359","BK1141","LU1046422090.SGD"],"gpt_icon":0},{"id":"2549545901","title":"港交所文件顯示，貝萊德H股持倉比例從7月2日的5.49%降至4.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549545901","media":"金十数据","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549545901?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 18:13","pubTimestamp":1751969628,"startTime":"0","endTime":"0","summary":"港交所文件显示， 贝莱德 (BLK.N)在 药明康德 (02359.HK)H股持仓比例从7月2日的5.49%降至4.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708181908a69cf7e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708181908a69cf7e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0052750758.USD","BK1583","02359","LU2125910500.SGD","LU1046422090.SGD","BK1576","LU0320764599.SGD","BK1141","LU2242644610.SGD","LU2045819591.USD","00388","LU0708995583.HKD","BK1131","80388","BLK"],"gpt_icon":0},{"id":"2549458095","title":"上海萊士：SR604注射液進入Ⅱb期臨牀試驗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2549458095","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549458095?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 18:09","pubTimestamp":1751969396,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["03347","BK0196","BK1141","002252","BK0028","BK0046","BK1583","BK0188","BK1576","BK0239"],"gpt_icon":0},{"id":"2549545314","title":"上海萊士(002252.SZ)：SR604注射液進入Ⅱb期臨牀試驗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2549545314","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549545314?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 18:07","pubTimestamp":1751969270,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海莱士 公告，公司近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了IIb期临床试验登记信息，试验名称为：评价SR604注射液在血友病A/B及先天性凝血因子Ⅶ缺乏症患者中的安全性、耐受性、有效性、PK/PD特征的开放、多中心Ⅰ/Ⅱ期临床试验。据公告所示，SR604注射液拟用于血友病A/B及先天性凝血因子Ⅶ缺乏症患者出血的预防治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0028","BK0188","BK0196","BK0239","002252","BK1576","03347","BK1583","BK1141"],"gpt_icon":0},{"id":"2549483335","title":"聯環藥業(600513.SH)：LH-1801項目從臨牀試驗成功到最終上市銷售並實現盈利 面臨多重關鍵環節的重大不確定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2549483335","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549483335?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 17:30","pubTimestamp":1751967041,"startTime":"0","endTime":"0","summary":"公司就LH-1801项目相关情况特别提示如下风险：1、临床数据阶段性结论与未来结果的不确定性：LH-1801项目临床试验采用非劣效设计，最终能否实现目标，存在重大不确定性。最终揭盲结果能否达到非劣目标结果、能否成功获得上市批准、以及获批上市后的具体时间均存在重大不确定性。综上所述，LH-1801项目从临床试验成功到最终上市销售并实现盈利，面临多重关键环节的重大不确定性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4550","LU0006061336.USD","LU0742534661.SGD","BK4196","03347","BK4588","BK1141","LU0048573561.USD","LU1059921491.USD","BK1583","LU0251131958.USD","BK4585","LU0251142724.SGD","BK0239","LH","BK1576","600513"],"gpt_icon":0},{"id":"2549753512","title":"【恆瑞醫藥(01276.HK)：SHR-2173注射液獲藥物臨牀實驗批准】智通財經APP訊，恆瑞醫藥(01276.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2549753512","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549753512?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 17:00","pubTimestamp":1751965246,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03347","BK0196","01276","LU0405327148.USD","BK0183","LU1969619763.USD","BK0239","LU0405327494.USD","BK1583","LU2148510915.USD","BK0188","BK0012","BK1576","LU2488822045.USD","LU1997245094.SGD","LU1655091616.SGD","BK0028","LU1328615791.USD","LU2495084118.USD","LU1064130708.USD","LU1997244956.HKD","LU1997245177.USD","LU1064131003.USD","BK1141","BK1191","600276","LU2328871848.SGD","BK0060"],"gpt_icon":0},{"id":"2549517350","title":"【恆瑞醫藥(01276.HK)附屬獲得國家藥監局核准簽發關於HRS-9821吸入粉霧劑的《藥物臨牀試驗批准通知書》】智通","url":"https://stock-news.laohu8.com/highlight/detail?id=2549517350","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549517350?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:58","pubTimestamp":1751965088,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01276","600276","BK0196","LU2495084118.USD","BK0060","BK0183","BK1576","BK1583","LU2488822045.USD","LU1328615791.USD","LU2148510915.USD","BK1191","LU1997244956.HKD","LU1655091616.SGD","LU1064130708.USD","BK0188","LU2328871848.SGD","LU0405327148.USD","LU0405327494.USD","BK1141","BK0012","BK0239","LU1969619763.USD","LU1064131003.USD","LU1997245094.SGD","03347","BK0028","LU1997245177.USD"],"gpt_icon":0},{"id":"2549514210","title":"【博瑞醫藥：噻託溴銨吸入粉霧劑獲藥物臨牀試驗批准】博瑞醫藥公告，控股子公司艾特美（蘇州）醫藥科技有限公司近日收到國家藥監局簽發的《藥物臨牀試驗批准通知書》，同意艾特美噻託溴銨吸入粉霧劑開展用於慢性阻塞性肺疾病（COPD）的臨牀試驗。噻託溴銨吸入粉霧劑2022年至2024年國內銷售額分別為5.55億元、5.22億元、4.93億元。藥品在獲得批准後尚需開展臨牀試驗並經批准後方可生產上市，短期內對公司經營業務不會產生較大影響。","url":"https://stock-news.laohu8.com/highlight/detail?id=2549514210","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549514210?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:43","pubTimestamp":1751964235,"startTime":"0","endTime":"0","summary":"博瑞医药公告，控股子公司艾特美（苏州）医药科技有限公司近日收到国家药监局签发的《药物临床试验批准通知书》，同意艾特美噻托溴铵吸入粉雾剂开展用于慢性阻塞性肺疾病（COPD）的临床试验。噻托溴铵吸入粉雾剂2022年至2024年国内销售额分别为5.55亿元、5.22亿元、4.93亿元。药品在获得批准后尚需开展临床试验并经批准后方可生产上市，短期内对公司经营业务不会产生较大影响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/08164351557624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK1161","BK1576","BK1515","09939","159938","BK1583","688166","03347","BK1141","BK1574"],"gpt_icon":0},{"id":"2549511128","title":"藥明康德(02359)7月8日斥資2000.76萬元回購28.5萬股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2549511128","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549511128?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:36","pubTimestamp":1751963791,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德(02359)发布公告，该公司于2025年7月8日斥资2000.76万元人民币回购28.5万股A股，每股回购价格为69.64-70.84元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603259","LU2328871848.SGD","LU1969619763.USD","LU2045819591.USD","BK1576","LU2495084118.USD","LU1997245094.SGD","LU2125910500.SGD","159982","02359","399300","LU2242644610.SGD","LU0708995583.HKD","LU1997245177.USD","LU0052750758.USD","LU0456842615.SGD","BK1141","LU0320764599.SGD","BK1583","LU1046422090.SGD","LU2488822045.USD","BK0216","LU1997244956.HKD"],"gpt_icon":0},{"id":"2549519632","title":"恆瑞醫藥(600276.SH)：HRS-9821吸入粉霧劑獲得藥物臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2549519632","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549519632?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:19","pubTimestamp":1751962755,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司子公司广东恒瑞医药有限公司收到国家药品监督管理局核准签发关于HRS-9821吸入粉雾剂的《药物临床试验批准通知书》，将于近期开展临床试验。据悉，HRS-9821是小分子PDE3/PDE4 抑制剂，可有效抑制呼吸道炎症、扩张支气管，临床拟用于COPD的维持治疗。目前全球同类产品仅Ensifentrine于2024 年7月在美国获批上市，用于COPD的维持治疗。截至目前，HRS-9821相关项目累计研发投入约3,843万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","LU2148510915.USD","LU1997244956.HKD","LU1655091616.SGD","LU0405327494.USD","BK0012","BK0188","BK1141","BK0239","LU1997245094.SGD","BK0183","BK1576","LU2328871848.SGD","LU0405327148.USD","LU1969619763.USD","LU1328615791.USD","LU1064130708.USD","LU1997245177.USD","BK1191","BK0060","LU1064131003.USD","BK0196","LU2488822045.USD","03347","BK1583","BK0028","LU2495084118.USD","600276"],"gpt_icon":0},{"id":"2549358510","title":"金斯瑞生物科技07月08日獲主力加倉1288.5萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549358510","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549358510?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:16","pubTimestamp":1751962563,"startTime":"0","endTime":"0","summary":"07月08日, 金斯瑞生物科技股价涨1.37%，报收14.84元，成交金额2.2亿元，换手率0.69%，振幅4.23%，量比0.71。金斯瑞生物科技今日主力资金净流入1288.5万元，连续3日净流入，上一交易日主力净流入767.1万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为50.00%，平均涨幅为3.34%。该股近5个交易日上涨0.68%，主力资金累计净流入1348.9万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流出1.8亿元，其中净流出天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170348a69ccd91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170348a69ccd91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000320223.HKD","01548","HK0000320264.USD","BK1583","HK0000306685.HKD","BK1141","HK0000306701.USD","BK1576"],"gpt_icon":0},{"id":"2549489145","title":"康龍化成07月08日主力淨流入2024.8萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2549489145","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549489145?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:16","pubTimestamp":1751962560,"startTime":"0","endTime":"0","summary":"07月08日, 康龙化成股价涨3.40%，报收17.02元，成交金额1.5亿元，换手率2.95%，振幅4.86%，量比1.45。康龙化成今日主力资金净流入2024.8万元，上一交易日主力净流出899.6万元。该股近5个交易日上涨4.15%，主力资金累计净流入1191.1万元；近20日主力资金累计净流出913.7万元，其中净流出天数为13日。该股主力净额占比0.40%，港股市场排名30/2669。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170248a69cccce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170248a69cccce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","03759","BK1576"],"gpt_icon":0},{"id":"2549512937","title":"維亞生物07月08日獲主力加倉98.1萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549512937","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549512937?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:15","pubTimestamp":1751962542,"startTime":"0","endTime":"0","summary":"07月08日, 维亚生物股价涨4.35%，报收1.44元，成交金额1016.1万元，换手率0.33%，振幅6.52%，量比0.85。维亚生物今日主力资金净流入98.1万元，连续3日净流入，上一交易日主力净流入26.7万元。该股近5个交易日下跌4.55%，主力资金累计净流出208.0万元；近20日主力资金累计净流出1017.9万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165615a69cc89e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165615a69cc89e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01873","BK1576","BK1141"],"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":12,"totalSize":252,"code":"91000000","status":"200"}]}}